U.S. doctors online nowAsk doctors free
Graceville, FL
A 19-year-old male asked:

What is all the controversy over actos (pioglitazone)?

1 doctor answer1 doctor weighed in
Dr. Philip Kern
Endocrinology 43 years experience
Media frenzy: Actos (pioglitazone) is a good drug for diabetes. All drugs in this class cause fluid retention, which can worsen heart failure in some people. A related drug (avandia) got slammed for increasing coronary heart disease, but this never affected actos (pioglitazone). These drugs may increase bone loss. Now there is a weak inference of bladder cancer, and the media and lawyers are all over this like sharks on fresh meat.

90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more. Get help now:

Ask doctors free
Educational text
Free
Talk to a doctor
24/7 visits - just $39!
50% off with $15/month membership

Related questions

A 40-year-old member asked:
1 doctor answer1 doctor weighed in
A 33-year-old member asked:
1 doctor answer1 doctor weighed in
A 39-year-old member asked:
1 doctor answer1 doctor weighed in
A 30-year-old member asked:
1 doctor answer2 doctors weighed in
A 30-year-old member asked:
1 doctor answer1 doctor weighed in

90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more. Get help now:

Ask doctors free
Educational text
Free
Talk to a doctor
24/7 visits - just $39!
50% off with $15/month membership
Last updated Jun 24, 2014

People also asked

Related topics

Connect with a U.S. board-certified doctor by text or video anytime, anywhere.
24/7 visits - just $39!
50% off with $15/month membership

Disclaimer:

Content on HealthTap (including answers) should not be used for medical advice, diagnosis, or treatment, and interactions on HealthTap do not create a doctor-patient relationship. Never disregard or delay professional medical advice in person because of anything on HealthTap. Call your doctor or 911 if you think you may have a medical emergency.